ABOUT THIS CONFERENCE
G protein-coupled receptors (GPCRs) are among the most common types of molecules that medicines work upon. These receptors continue to be a focus of new drug discovery not only due to their cell surface location which makes them accessible to ingested therapies, but also because of the role they play in so many cell types as the 'sensor or transmitter' of extra-cellular chemical signals into messages that result in cellular change.
Two back-to-back GPCR conferences will cover the challenges faced with the industry's current paradigm of target-driven discovery.
GPCR-Based Drug Discovery, the first day and a half conference of our back-to-back GPCR conferences, will cover screening and discovery strategies for compounds, including allosteric modulators, acting on GPCRs. A few talks will also be devoted to the findings and impact of the slew of recent crystal structures of medically relevant GPCRs that have been elucidated. New assays to uncover or methods to direct ligand-biased signaling will be another focus of the conference.
SUGGESTED EVENT PACKAGE:
September 23: Practical Aspects of Structure-Based Drug Discovery with GPCRs Short Course 2
September 23: Allosteric Modulators of GPCRs Short Course 4
September 24 - 25: GPCR-Based Drug Discovery Conference
September 25 - 26: GPCR-Targeted Therapies Conference
Day 1 | Day 2 | Download Brochure
Tuesday, September 24
7:00 am Registration and Morning Coffee
8:10 Chairperson’s Opening Remarks
8:15 Structural insights into Function and Pharmacology of
GPCR Superfamily
Vsevolod (Seva)
Katritch, Ph.D., Assistant Professor, The Scripps
Research Institute
8:45 FEATURED PRESENTATION: Molecular Signatures of GPCRs
Christopher Tate, Ph.D., Professor, Laboratory of Molecular
Biology, MRC, United Kingdom
9:15 GPCR Ligand Design via
SAR-Guided Homology Models
Mark Bures, Ph.D., Research Advisor,
Computational Chemistry, Eli Lilly
9:45 Grand Opening Coffee Break in the Exhibit Hall with
Poster Viewing
ANTIBODIES AND GPCRs
10:45 Nanobodies for the Structural
and Functional Characterization of GPCR Transmembrane
Signaling: From Structure to Function to Drugs
Jan Steyaert, Ph.D., Head of
Department, Structural Biology, Vrije University
Brussels, Belgium
11:15 Antibodies Against Difficult Targets: How to Tackle G-Protein Coupled ReceptorS
Stefanie Urlinger, Ph.D., Director,
Research & Development, MorphoSys AG
11:45 Monoclonal Antibodies against Endothelin
A and B Human GPCR Subtypes
Frederic Ducancel, Ph.D., Head,
Laboratory, Institute of Biology and Technology, Saclay,
Atomic Energy Commission, France
12:15 pm Preclinical and Clinical Experience with PRO 140, a
Humanized Anti-CCR5 Antibody for the Treatment and Prevention of HIV
Richard Trauger, Ph.D., CSO, CytoDyn
12:45 A Novel Regulatory Role of a Humanized Anti-CCR4
Antibody in Cancer Immunotherapy
DeKuan Chang, Ph.D., Research
Fellow, Cancer Immunology & AIDS, Dana-Farber Cancer Institute
1:15 LUNCHEON PRESENTATION: New Era of GPCR Drug Discovery: Multi-Pathway Screening Technologies
Elizabeth R. Quinn, Ph.D., Director, LeadHunter
Discovery Services, DiscoveRx Corporation
2:15 Chairperson’s Opening Remarks
2:20 FEATURED PRESENTATION: Allosteric
Regulation of G Protein-Coupled Receptors: Implications to Functionally
Selective Ligand Pharmacology
Roger K Sunahara, Ph.D., Associate
Professor, Pharmacology, University of Michigan Medical School
2:50 Discovery of style='font-family:"Arial","sans-serif"'>β-
Arrestin-Biased Agonists of Dopamine D2 Receptors
Kyle Butler, Ph.D., Post-Doctoral Fellow, Laboratory of
Jian Jin, Division of Chemical Biology and Medicinal
Chemistry,The University of North Carolina at Chapel Hill
3:20 Sponsored Presentation (Opportunity Available)
3:50 Refreshment Break in the Exhibit Hall with Poster Viewing
4:30 Directed Evolution of Conformationally-selective
GPCR Antibodies and Applications to Discovering Biased Ligands
Aaron Ring, MD/PhD candidate, Laboratory of K. Christopher
Garcia, Department of Structural Biology, Stanford University School of
Medicine
5:00 GPCR-Biased Ligands as Improved
Therapeutics: Promise and Progress
Jonathan Violin, Ph.D., Director, Biology, Trevena,
Inc.
5:30 Interactive Breakout Discussion Groups
6:30 Welcome Reception in the Exhibit Hall with Poster Viewing
7:30 Close of Day
Day 1 | Day 2 | Download Brochure